by John Miller | Sep 2, 2019 | Pharmaceutical
FILE PHOTO: Logo of Swiss drugmaker Novartis is seen at its branch in Schweizerhalle near Basel, Switzerland, March 29, 2018. REUTERS/Arnd Wiegmann/File Photo ZURICH (Reuters) – Swiss drugmaker Novartis on Friday stepped up its challenge to Roche’s multiple...
by Manojna Maddipatla | Aug 21, 2019 | Pharmaceutical
FILE PHOTO: The logo of Swiss drugmaker Roche is seen at its headquarters in Basel, Switzerland (Reuters) – Roche Holding AG has priced at about $204,560 a year its personalized cancer treatment, Rozlytrek, that targets tumors with specific genetic mutations,...
by No author. | Jun 17, 2019 | Oncology, Pharmaceutical
FILE PHOTO: Brad Zakes (L), founder of Ethan Zakes Foundation/CEO of Cerevast Medical, and Nick Leschly, CEO of bluebird bio at the opening of Swiss pharmaceutical group Lonza’s dedicated cell and gene therapy facility in Houston, Texas, U.S., April 10, 2018....
by jbolanosmd | Oct 4, 2018 | Hospitals, Mergers & Acquisitions, Pharmaceutical
SEPTEMBER 28, 2018 — 10:40PM Joe Carlson / Star Tribume UnitedHealth has said that transforming pharmacy care services is a key goal it hopes to accomplish. UnitedHealth Group’s OptumRx division for pharmacy services is combining operations with a large,...
by Alexander Smith and Jane Merriman | Sep 28, 2018 | Oncology, Pharmaceutical
LONDON (Reuters) – AstraZeneca’s immunotherapy drug Imfinzi cut the risk of death in patients with mid-stage lung cancer by nearly a third in a closely watched clinical study, reinforcing the case for using the drug in earlier disease. A sign is seen at an...
by John Miller | Sep 28, 2018 | BioPharma, Oncology, Pharmaceutical
ZURICH (Reuters) – Swiss drugmaker Roche upped its bet on personalized cancer treatment on Monday, saying it is now ready to sell a blood test around the world that can identify common gene mutations from solid tumors from a patient’s blood. The blood test,...
